In HER2-positive breast cancers, IL-6 expression can induce CSC-positive phenotype through activating NF-κB and STAT3 pathways, thus driving tumorigenesis and promoting chemotherapy resistance (Liu S. et al., 2018). This evidence concerns the gene IL6 and breast cancer.